All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CVnCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Wacker Chemie AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 23, 2020
Details:
Under the terms of the initial agreement, WACKER will ramp up GMP (Good Manufacturing Practice) production of the mRNA drug substance for CVnCoV at its biotech site in Amsterdam in the first half of 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): mRNA-based vaccines
Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: European Commission
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 16, 2020
Details:
The mRNA vaccine will be supplied once it has proven to be safe and effective against COVID-19. CureVac will receive an upfront payment to support the advanced clinical development of CVnCoV, to ramp-up its manufacturing network, and market launch and supply preparations.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CVnCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
CVnCoV, was generally well tolerated and trial results strongly supported the company’s plans to launch the final stage of testing involving about 30,000 participants before the end of the year.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BI 764198
Therapeutic Area: Infections and Infectious Diseases Product Name: BI 764198
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2020
Details:
The aim of therapy with BI 764198 is to reduce the need for ventilator support, to improve patient recovery rate & ultimately to save lives. This may alleviate the damage to lung & decrease the severity of acute respiratory complications in patients hospitalized for COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CVnCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2020
Details:
CVnCoV elicited balanced humoral and cellular immune responses, featuring high antibody titers and very good T cell activation. In addition to the positive immune response, the vaccine candidate induced favorable Th1 cytokine levels.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Asunercept
Therapeutic Area: Infections and Infectious Diseases Product Name: APG101
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
The ASUNCTIS trial is a multi-center, randomized, controlled, open-label phase II trial to assess the efficacy and safety of asunercept in patients with severe COVID-19 disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CVnCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
The study design was coordinated with and approved by the health authorities and ethics committees of Peru and Panama and is based on preliminary safety and immunogenicity data from CureVac’s ongoing Phase 1 CV-NCOV-001 study in healthy adult volunteers in Germany and Belgium.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Asunercept
Therapeutic Area: Infections and Infectious Diseases Product Name: APG101
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2020
Details:
The ASUNCTIS trial will be a multi-center, randomized, controlled, open-label trial to assess the efficacy and safety of asunercept in patients with severe COVID-19 disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATR-002
Therapeutic Area: Infections and Infectious Diseases Product Name: ATR-002
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2020
Details:
ATR-002 is an oral small molecule, in a dose escalation study demonstrated excellent safety and tolerability and the observed pharmacokinetic profile supports the intended once-daily regime for the upcoming Phase II clinical development.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pritelivir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2020
Details:
Receiving Breakthrough Therapy Designation will facilitate AiCuris goal of bringing pritelivir to patients as quickly as possible . Company is now preparing to add a pivotal Phase 3 trial part to the ongoing Phase 2 study in immunocompromised patients.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
